Related Experiment Video

Updated: Jul 15, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis

Yoshimasa Aso1

  • 1Department of Internal Medicine, Koshigaya Hospital, Dokkyo Medical University, Saitama, Japan. yaso@dokkyomed.ac.jp

Frontiers in Bioscience : a Journal and Virtual Library
|May 9, 2007
PubMed

Insights

Elevated levels of plasminogen activator inhibitor (PAI)-1 impair fibrinolysis, contributing to atherothrombotic cardiovascular disease (CVD) in diabetes and metabolic syndrome. This PAI-1 contributes to vascular inflammation and plaque formation.

Area of Science:

  • Cardiovascular Science
  • Metabolic Disease Research
  • Hemostasis and Thrombosis

Background:

  • Impaired fibrinolysis is linked to atherothrombotic cardiovascular disease (CVD), particularly in metabolic syndrome and type 2 diabetes.
  • Elevated plasma levels of plasminogen activator inhibitor (PAI)-1, a key fibrinolysis inhibitor, are observed in conditions associated with high CVD incidence.

Purpose of the Study:

  • To investigate the role of elevated plasminogen activator inhibitor (PAI)-1 in the development of atherothrombotic cardiovascular disease (CVD).
  • To explore the association between PAI-1, impaired fibrinolysis, and vascular inflammation in the context of metabolic syndrome and type 2 diabetes.

Main Methods:

  • Analysis of PAI-1 levels in plasma and atherosclerotic lesions.
  • Assessment of fibrin accumulation and neointima formation.
  • Evaluation of PAI-1's potential involvement in vascular inflammation.

Main Results:

  • High plasma PAI-1 is associated with impaired fibrinolysis and excessive fibrin accumulation, leading to atherothrombosis.
  • Increased PAI-1 expression is found in human atherosclerotic lesions, especially in type 2 diabetes patients.
  • Vascular PAI-1 promotes neointima formation by inhibiting the clearance of platelet-fibrin thrombi.

Conclusions:

  • Elevated PAI-1 contributes to atherothrombosis by impairing fibrinolysis and promoting fibrin accumulation.
  • PAI-1 may play a role in vascular inflammation and is implicated both systemically and locally in CVD development.
  • Targeting PAI-1 could be a therapeutic strategy for preventing CVD in at-risk populations.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...